Volume 14, Number 9—September 2008
Pediatric Parapneumonic Empyema, Spain
|Characteristic||HIDP serotypes, n = 84||Serotype 3, n = 11||LIDP serotypes, n = 13||p value|
|Median age, mo (range)||55.6 (2–180)||37.9 (9–71)||24 (2–36)||0.0001†|
|Median hospital stay,‡ d (range)||13 (4–38)||15 (9–29)||10 (6–24)||0.042§|
|Complications, % patients¶||10||45||0||0.004#|
*PPE, pediatric parapneumic empyema; HIDP, high invasive disease potential; LIDP, low invasive disease potential. HIDP serotypes: 1, 5, 7F, and 14; LIDP serotypes: 6A, 9V, 19A, and 19F (16,17,19). All results shown were statistically significant (p<0.05). There were no significant differences between groups for the following variables: median days febrile preadmission; preadmission antimicrobial therapy; intensive care unit admission; mean leukocyte count; mean C-reactive protein; mean pleural fluid glucose; mean pleural fluid pH; mean lactate dehydrogenase; median days to thorachocentesis; referral; primary fibrinolytics or thoracoscopy; or oxygen requirement >4 d.
†HIDP was compared with LIDP by post hoc analysis.
‡Since being admitted to first center.
§No significant differences between individual groups by post hoc analysis (p = 0.023 for comparison between serotype 3 and LIDP)
¶Complications included (no. patients): bronchopleural fistula (3), pyopneumothorax (2), pneumatoceles (4), lung abscess (1), mechanical ventilation
>48 h (2), severe anemia requiring blood transfusion (2), severe hypoalbuminemia requiring seroalbumin replacement (1).
#Serotype 3 compared with HIDP and LIDP groups combined.
- Page created: July 13, 2010
- Page last updated: July 13, 2010
- Page last reviewed: July 13, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)